- 2023 Multidisciplinary Oncology Review
- 2022
- Videos
- 2021
- 2020
- 2019
- Hematology & Medical Oncology Review 2019
- 2018
- Events
Playback speed
10 seconds
2020 ASCO Highlights on NSCLC Targeted Therapy: T-DXd for HER2-Mutated, Capmatinib for MET-Amplified, Selpercatinib (LOXO-292) for RET-Altered, Adjuvant Osimertinib for EGFR+ Disease
0 views
September 9, 2020
Comments 0
Login to view comments.
Click here to Login
2020 ASCO Highlights